The great complexity of many human pathologies, such as cancer, diabetes, and neurodegenerative diseases, requires new tools for studies of biological processes on the whole organism level. The discovery of novel biocompatible reactions has tremendously advanced our understanding of basic biology; however, no efficient tools exist for realtime non-invasive imaging of many human proteases that play very important roles in multiple human disorders. We recently reported that the "split luciferin" biocompatible reaction represents a valuable tool for evaluation of protease activity directly in living animals using bioluminescence imaging (BLI). Since BLI is the most sensitive in vivo imaging modality known to date, this method can be widely applied for the evaluation of the activity of multiple proteases, as well as identification of their new peptide-specific substrates. In this unit, we describe several applications of this "split luciferin" reaction for quantification of protease activities in test tube assays and living animals. Curr.
INTRODUCTION
The discovery of biocompatible reactions had a significant impact on chemical biology and allowed studies of many biological processes directly in living systems. However, despite the fact that multiple biocompatible reactions have been developed in the past decade, very few work efficiently in complex living organisms. We previously reported that D-cysteine and 2-cyanobenzothiazole (CBT) can selectively react with each other in vivo to generate luciferin substrates for firefly luciferase ("split luciferin reaction," Fig. 1 ) (Godinat et al., 2013) .
Since the production of luciferin substrates can be visualized and quantified directly in genetically modified living animals by bioluminescence imaging (BLI), it has immediate application for studies of many biological processes. For example, this reaction is well suited for interrogation of targeted tissues using a "caged" luciferin approach. This technique is based on the fact that luciferins caged on the phenolic oxygen or aryl nitrogen do not lead to light production (Wehrman et al., 2006; Cohen et al., 2010; van de Bittner et al., 2010; Henkin et al., 2012) (Fig. 2) . Despite the fact that caged luciferin compounds have been previously generated to quantify activities of several biological processes (Shah et al., 2005; Goun et al., 2006; Wehrman et al., 2006; Cosby et al., 2007; Yao et al., 2007; Dragulescu-Andrasi et al., 2009; Biserni et al., 2010; Cohen et al., 2010; Hickson et al., 2010; van de Bittner et al., 2010; Scabini et al., 2011; Henkin et al., 2012) , the synthesis of their scaffolds involves much more complex and low-yielding synthetic procedures, representing a major limitation of this technology (Massoud and Gambhir, 2003; McCaffrey et al., 2003; Liu et al., 2005; Shah et al., 2005; Wehrman et al., 2006; Yao et al., 2007; Dragulescu-Andrasi et al., 2009; Cohen et al., 2010; Prescher and Contag, 2010; Reddy et al., 2010; van de Bittner et al., 2010; Harwood et al., 2011; Conley et al., 2012; Henkin et al., 2012; Liang et al., 2012a,b; McCutcheon et al., 2012) .
We previously reported application of this "split luciferin reaction" for the real-time and non-invasive imaging of apoptosis, associated with activation of caspase 3/7 (Godinat et al., 2013) . Caspase-dependent release of free D-cysteine from the caspase 3/7-specific peptidic substrate Asp-Glu-Val-Asp-D-Cys [DEVD-(D-Cys)] allowed further reaction with 6-amino-2-cyanobenzothiazole (NH 2 -CBT) in vivo and subsequent formation of 6-amino-D-luciferin. Since this compound is known to be an excellent substrate for luciferase, its formation leads to the generation of light that is proportional to the activity of caspase 3/7. Importantly, this "split luciferin" strategy was found to be more sensitive when compared to the commercially available DEVD-aminoluciferin substrate (Godinat et al., 2013) , in which the entire luciferin is caged with the same peptidic sequence. The underlying principle of the use of "split luciferin reaction" for protease imaging is depicted in Figure 3 using caspase 3/7 peptide-specific sequence (DEVD) as an example.
This result was particularly exciting because the "split luciferin" approach can now be applied for imaging and quantification of many other proteases that are known to cleave Figure 3 Imaging of caspase 3/7 activity using the "split luciferin" reaction. Modification on the D-cysteine moiety with DEVD sequence allows selective formation of D-luciferin upon caspase-3/7 cleavage and subsequent production of light, proportional to activity of caspase 3/7. Adapted with permission from Godinat et al. (2013) . Copyright 2014 American Chemical Society.
Figure 4
Overall representation of the dual imaging concept for luciferin ligation. Both luciferin ligation precursors could be caged as sensors for two different biomolecules. Only when both become uncaged, D-luciferin or Daminoluciferin is formed as the result of split luciferin ligation reaction, allowing the production of light by luciferase enzyme. Reprinted with permission from Godinat et al. (2013) . Copyright 2014, American Chemical Society. at the end of specific amino acid sequences (Wilson et al., 2002; Cali et al., 2006; Zhou et al., 2006a,b; Yao et al., 2007) , as well as identification of new protease-specific peptides associated with various human diseases. Immediate examples of mammalian proteases include dipeptidyl peptidase 4 (GP and VP), tryptase (PRNK), and various caspases such as caspase 2 (VDVAD), caspase 6 (VEID), caspase 8 (LETD), caspase 9 (LHTD), and caspase 12 (ATAD) (O'Brien et al., 2005; Cali et al., 2006; Geiger et al., 2006; Zhou et al., 2006a,b; Ren et al., 2009 ). In addition to mammalian proteases, this "split luciferin" methodology could also be used for studies of a wide variety of viral, parasite, and bacterial proteases that play very important roles in the replication and the spread of infectious diseases (Wilson et al., 2002) . They include SARS protease (TSAVLQ), caspase-like (nLPnLD), and trypsin-like (LRR) proteases (Cali et al., 2006; Geiger et al., 2006; Zhou et al., 2006a,b) .
Importantly, the synthesis of short peptide sequences with C-terminal D-cysteine can be easily performed with the help of automated peptide synthesis, which is a widely available and versatile technique (Merrifield, 1965; Merrifield and Stewart, 1965) . On the contrary, the synthesis of caged luciferin substrates like DEVD-aminoluciferin represents a major synthetic challenge, which is reflected by a very high cost of commercially available probes. Moreover, the new approach suits itself perfectly for multiplex imaging based on the modular construction of bioluminogenic sensors, where either or both reaction partners (D-Cys and CBT) are caged to report on multiple biological events (Fig. 4) . Therefore, we believe that this protocol can be applied to evaluation of activity of multiple biologically important proteases that are known to cleave at the end of corresponding specific amino acid sequences and allow sensitive imaging and quantification of their activities directly in animal models of disease.
Basic Protocol 1 describes the methodology for imaging and quantifying protease activity in a cell-free in vitro experimental setup. The procedure is detailed for caspase-3 imaging. Thrombin protease activity imaging is also described in the Alternate Protocol. Finally, Basic Protocol 2 describes in detail the use of "split luciferin" based bioluminescent probes for real time non-invasive caspase-3/7 imaging in luciferase-expressing mice.
NOTE: All protocols using live animals must first be reviewed and approved by an Institutional Animal Care and Use Committee (IACUC) or must conform to governmental regulations regarding the care and use of laboratory animals.
BASIC PROTOCOL 1

IN VITRO (CELL-FREE) BIOLUMINESCENCE IMAGING OF PROTEASE ACTIVITY USING "SPLIT LUCIFERIN" REACTION
The following procedure describes in detail all the steps necessary for evaluation of activity of thrombin and caspase 3 proteases in a plate reader format. However, the same approach can be adapted to studies of activity of other proteases that are known to cleave their peptide-specific sequences on the C-terminal of the cleavage site.
The development of novel probes for evaluation of protease activities should start from the selection of protease-specific amino-acid sequence that can be selectively recognized and cleaved by a protease of interest (POI). When such sequence is selected, a D-cysteine (DCys) residue should be introduced at the C-terminal position using common and widely used automated or manual peptide synthesis techniques (Merrifield, 1965; Merrifield and Stewart, 1965) . If evaluation of thrombin or caspase 3/7 proteases are intended, the exact protocol described below should be followed. To test the viability of this approach with the desired POI, the selected peptide containing the D-Cys on the C-term will be incubated with the purified POI. After addition of CBT and luciferase enzyme, light emission will be acquired.
Example with caspase 3
In the first step, activated caspase-3 enzyme is incubated with DEVD-(D-Cys) peptide. Once cleaved by the protease, the resulting D-Cys reacts with NH 2 -CBT leading to the formation of amino-D-luciferin and further light production, proportional to the activity of caspase 3 (Fig. 3 ). An example of the data that was acquired for quantification of caspase-3 activity in vitro using the split luciferin approach is depicted in Figure 5 ( Godinat et al., 2013) . In these experiments, the DEVD-(D-Cys) probe was incubated with increasing concentrations of caspase-3 followed by addition of NH 2 -CBT. The resulting light emission was acquired over 2 hr and plotted as a function of time (Fig. 5A) . Quantification of the total light produced over this period of time was performed by integrating the area under the curves and plotting in the form of bar-graph (Fig. 5B ).
Caspase-3 was purified and characterized following the reported procedure (Stennicke and Salvesen, 1999) . , and 100 nM) over 3 hr at 37°C, followed by addition of NH 2 -CBT (400 μM in MeOH), and incubation for additional 1 hr at 37°C. The signal acquisition was started immediately after addition of 5 μl of the premade luciferase buffer (see recipe) and acquired for the duration of 2 hr using the IVIS Spectrum (Perkin Elmer). (Error bars are ± SD for three measurements.) (B) Total light output collected over the period of 2 hr (performed by integrating the area under the curves in panel A and plotted in the form of a bar-graph). Adapted with permission from Godinat et al. (2013 0 nM: only caspase buffer 50 nM: dilute 100 μl of 200 nM caspase-3 stock solution to 400 μl using caspase buffer 100 nM: dilute 200 μl of 200 nM caspase-3 stock solution to 400 μl using caspase buffer 2. Add caspase-3 solutions (0, 50, 100 nM) in triplicate to a V-shaped 96-well plate with 50 μl per well.
3. Add 200 nM caspase-3 stock solution into six wells of the same plate with 50 μl per well.
4. Cover the plate with a lid to avoid evaporation and incubate for 15 min at 37°C in order to activate the caspase-3 enzyme.
5. Add 50 μl of 800 μM D-cysteine solution into three of the wells containing the 200 nM caspase-3 solution.
6. Add 50 μl of 800 μM DEVD-(D-Cys) solution into all of the other wells.
7. Cover the plate with a lid to avoid evaporation and incubate for 3 hr at 37°C.
8. Add 100 μl of the 400 μM NH 2 -CBT solution into each well. Mix the solutions by pipetting up and down several times.
9. Protect the plate from light and incubate for 1 hr at 37°C.
10. Prepare a second 96-well plate by adding 115 μl of the 60 μg/ml luciferase solution per well. 
ALTERNATE PROTOCOL
IN VITRO (CELL-FREE) IMAGING OF THROMBIN PROTEASE ACTIVITY
This alternate protocol focuses on the evaluation of thrombin protease activity using thrombin-specific Gly-Gly-Arg-(D-Cys) [GGR-(D-Cys)] peptide, which is designed to be cleaved by thrombin protease between Arg and D-Cys residues.
Thrombin enzyme is first incubated with GGR-(D-Cys) peptide. Upon enzymatic cleavage of peptidic sequence, D-Cys is liberated and reacts with NH 2 -CBT, resulting in the formation of D-aminoluciferin and further produces light that is proportional to the activity of thrombin enzyme. Figure 6 is an example of the data acquired for this experiment ( Fig. 6 ) (Godinat et al., 2013) . In this study, GGR-(D-Cys) peptide was first incubated with increasing concentration of thrombin enzyme, followed by addition of NH 2 -CBT. Subsequent light emission was acquired over 2 hr (Fig. 6A) . Integration of the area under each curve represent total photon flux produced over this time period and plotted in the form of bar-graphs in Figure 6B . 0 U/ml: only thrombin buffer 250 U/ml: dilute 20 μl of 1000 U/ml thrombin stock solution to 80 μl using thrombin buffer (1:4 dilution) 500 U/ml: dilute 40 μl of 1000 U/ml thrombin stock solution to 80 μl using thrombin buffer (1:4 dilution) 2. Add thrombin solutions (0, 250, 500 U/ml) in triplicates into a V-shaped 96-well plate with 20 μl per well.
3. Add 1000 U/ml thrombin stock solution into six wells of the same plate with 20 μl per well.
4. Add 80 μl of 500 μM D-cysteine solution into the three wells containing the 250 U/ml thrombin stock solution 5. Add 80 μl of 500 μM solutions of GGR-(D-Cys) peptide solution to all the other wells.
6. Cover the plate with a lid to avoid evaporation and incubate for 3 hr at 37°C.
7. Add 100 μl of 400 μM NH 2 -CBT solution to all of the wells. Mix the solution by pipetting "up and down."
8. Protect the plates from light and incubate for 1 hr at room temperature.
9. Prepare a second 96 well-plate by adding 115 μl of the 60 μg/ml luciferase solution per well. 
REAL-TIME NON-INVASIVE IMAGING OF CASPASE-3/7 ACTIVITIES IN TRANSGENIC REPORTER MICE (FVB-Luc+)
In this protocol, the procedure for evaluation of caspase-3/7 activity in living animals is described in details. It consists of two major parts: (1) induction of caspase-3/7 in live animals; (2) imaging steps using the "split luciferin" approach (Fig. 7) . A commercial kit is now available for the second step based on this technology ["Caspase 3 and Caspase 7 mouse kit (z-DEVD-D-Cys)", Intrace Medical].
In this study, we used transgenic mice ubiquitously producing luciferase in every cell of their body under actin promoter (Cao et al., 2004) . These and several other types of transgenic mice with luciferase expression in different organs are commercially available (from Taconic or The Jackson Laboratory).
Caspase 3/7 was induced in the liver of FVB-luc+ mice by injecting the animals with lipopolysaccharide (LPS) and D-galactosamine (D-GalN), following a procedure that was previously established for bioluminescence imaging of caspase-3/7 (Biserni et al., 2010) . Six hours post-administration of LPS and D-GalN, animals were injected with Figure 7 Imaging of caspase-3 activity in live FVB+luc animals using the "split luciferin" approach. Adapted with permission from Godinat et al. (2013) . Copyright 2014, American Chemical Society.
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Volume 6 Current Protocols in Chemical Biology "split luciferin" substrates [DEVD-(D-Cys) and NH 2 -CBT, Intrace Medical] and the signal was acquired using IVIS Spectrum camera (Perkin Elmer) (Godinat et al., 2013) . Commercially available DEVD-aminoluciferin compound was used as a positive control and for comparison. The data resulting from this experiment are shown on Figure 8 .
Taking into account that the current protocol could be potentially used in a different type of mouse or animal disease models, we thought it appropriate to add a few important points. Expression of firefly luciferase is mandatory in order to obtain readout using this approach. The animals can express luciferase ubiquitously, as in our study, or only in certain organs or tissues (like xenografts models or spontaneous cancer models where tumor cells express luciferase). It is also recommended that mice selected for the experiment should preferably be of approximately the same sex, age, and weight.
The amount of light output depends on the amount/level of luciferase expression that becomes particularly important if tumor models are used. In order to account for the difference in levels of luciferase expression between animals, the experiment should start with quantification of "basal" level of light resulting from administration of D-luciferin. This data set is important and can be later used for "calibration" of resulting signal from protease activation to the basal level of luciferase expression in each mouse. 2. Preload 0.5-ml insulin syringes with 100 μl of the luciferin solution.
3. Place the mice into a clear Plexiglas anesthesia box (3% isoflurane) that allows unimpeded visual monitoring of the animals.
Depending on the imaging system used, as well as the legislation that applies in the country where experiments are performed, other anesthesia methods could be used
4. Once the mice are fully anesthetized, inject them intraperitoneally (i.p.) with 100 μl of the corresponding D-luciferin solutions.
5. Place the mice on the heating pad (37°C) in the imaging chamber and keep them under anesthesia during the entire imaging period (it is advised to decrease the overall level of anesthesia to the equivalent of 1.5% isoflurane for imaging sessions over 1 hr).
6. Acquire bioluminescent signals for about 1 hr, recording measurements every 1 to 5 min.
In order to minimize the time between D-luciferin injection and the beginning of data acquisition, it is advised to preload syringes with corresponding solutions prior to the anesthesia step. Once all the mice are anesthetized, they should be injected sequentially and placed in the imaging chamber right after. The resting time between two imaging sessions might vary depending on the legislation that applies in the country where experiments are performed. It is also important to ensure that no residual signal is left from previous imaging with luciferin before starting step 10.
Therefore, it is advised to perform quick imaging of mice before proceeding with the next imaging step.
8. Prepare two experimental groups of animals defined as "treatment group" and "control group." Label each group of mice according to the legislation that applies in the country where the experiment is performed (at least four mice per group is recommended).
Activate caspase-3 9. Prepare 300 μl of a sterile solution of lipopolysaccharides (LPS) in PBS at 50 μg/ml. 11. Prepare 500 μl of a sterile solution of PBS.
12. Preload 0.5-ml insulin syringes with 50 μl of sterile LPS solution (one for each animal in the "treatment group").
13. Preload four syringes with 50 μl of sterile D-GalN solution (one for each animal in the "treatment group").
14. Preload four syringes with 100 μl of sterile PBS (one for each animal in the "control group").
15. Inject the four mice from the "treatment group" intraperitoneally (i.p.) with 100 μg/kg of LPS in 50 μl sterile PBS (one for each animal in the "control group").
An average 25 g mouse should receive a total amount of 2.5 μg LPS injected in 50 μl of sterile PBS solution (50 μg/ml).
16. Inject the same four mice from the "treatment group" i.p. with 267 mg/kg D-GalN in 50 μl of sterile PBS.
A typical 25 g mouse should receive a total amount of 6.7 mg D-GalN in 50 μl of sterile PBS solution (133.5 mg/ml).
17. Inject the "control group" of mice i.p. with 100 μl of sterile PBS.
18. Return all of the mice to their cages and wait 6 hr before proceeding the next step. 
An average 25 g mouse should receive a total amount of 0.565 mg of DEVD-(D-Cys) peptide in 100 μl of sterile PBS (5.65 mg/ml solution of the peptide in sterile PBS).
A delay of 10 min is respected before proceeding to the next step.
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23. Place the animals from the "treatment group" into a clear Plexiglas anesthesia box (3% isoflurane) that allows unimpeded visual monitoring of the animals.
24. Preload syringes with 20 μl of sterile NH 2 -CBT (one for each mouse in the "treatment" group).
25. After the mice are fully anesthetized, inject the mice i.p. with a 6.8 mg/kg dose of NH 2 -CBT solutions in 20 μl in sterile DMSO. 26. Place the mice on the heating pad (37°C) in the imaging chamber and keep them under anesthesia during the entire imaging period (it is advised to decrease the overall level of anesthesia to equivalent of 1.5% isoflurane for imaging sessions over 1 hr).
27. Acquire bioluminescent signals for ß1 hr, recording measurements every 1 to 5 min.
28. After the end of data acquisition, sacrifice the mice from "treatment group" according to the legislation that applies in the country where experiments are performed.
29. Repeat the experiment from steps 18 to 27 with the "control group."
30. After the end of data acquisition, turn off the instruments and return the mice from the "control group" back to their cages (they normally do not have to be sacrificed due to non-invasive nature of the control experiments). (Fig. 8C,D) . To calculate the overall light emission per mouse during the complete imaging time, areas under the curves are calculated and plotted in a bar graph (see Fig. 8A ).
Perform data analysis.
Data analysis is performed using Living Image In Vivo Software (PerkinElmer). Regions of interest (ROI) are defined around each animal. Mice tails are not taken into account in the ROI. This is performed for every time point and quantified values are plotted in function of time
REAGENTS AND SOLUTIONS
Use Milli-Q purified water or equivalent in all recipes and protocol steps. 
6-Amino-2-cyanobenzothiazole (NH
6-Amino-2-cyanobenzothiazole solution, 400 μM
Dissolve 1 mg of 6-amino-2-cyanobenzothiazole (mol. wt. 175.20 g/mol) in 1.427 ml of pure methanol. Once dissolved, take out 200 μl of this solution and further dilute to 2000 μl with methanol to obtain a 400 μM solution. Firefly luciferase enzyme, 60 μg/ml Dissolve 1 mg of firefly luciferase (Sigma Aldrich) in 16.7 ml of luciferase buffer (see recipe). Alternatively, a 2 mg/ml stock solution of Firefly luciferase can be prepared in PBS.
DEVD-(D-
100 μl of the stock solution will then be diluted up to 3.333 ml with luciferase buffer (see recipe) in order to obtain the desired 60 μg/ml luciferase solution. 
Purified caspase-3, 200 nM
Caspase-3 can be purified and characterized following the reported procedure (Stennicke and Salvesen, 1999 
Thrombin stock solution
Thrombin enzyme (Sigma-Aldrich, cat. no. T1063-1KU) is used without additional purification steps 1000 U/ml thrombin stock solution is prepared by diluting 1000 U of thrombin enzyme in 1 ml storage buffer (see recipe)
Thrombin stock solution should be stored at −20°C and multiple freeze/thaw cycles should be avoided. (Godinat et al., 2013) . This novel technology opens up new ways for imaging many biological processes and can even be used for dual analyte detection, as reported recently for simultaneous imaging of caspase-8 and hydrogen peroxide (van de Bittner et al., 2013) . Moreover, this novel technology could be applied for studies of many other proteases that are known to cleave at the end of peptidic sequences using sensitive bioluminescent imaging.
Critical Parameters
Multi-well plates Even though several types of 96-well or similar plates could be used in this experiment, it is essential that the chosen plates are compatible with bioluminescent imaging and have been validated with the equipment available. For example, we propose to first measure the background signal from the plate with PBS solution before starting the real measurements. Careful attention must be paid to those parameters in order to maximize assay sensitivity.
Choice of animal model
Many animal models can be used for this study. However, in order to obtain light emission, the animals should express luciferase either ubiquitously or in certain organs or tissues. For example, animals ubiquitously expressing luciferase under control of the betaactin promoter, as well as mice expressing luciferase in certain organs, are now commercially available (The Jackson Laboratory). Alternatively, animals can be injected with luciferase-expressing cells subcutaneously, intraperitoneally, intravenously, by an intracardiac route, or orthotopically.
In order to quantify the signal from protease activation, it is important to determine the basic level of expression of the luciferase enzyme, as it will greatly influence the amount of light produced. It is particularly important when this experiment is performed in tumor models where the tumor size differs significantly from one animal to another. The basic level of luciferase expression should be measured before activation of protease step, and these data can be used for calibration to the level of protease expression. For generation of these data, please follow Basic Protocol 2 (steps 1 to 8).
In addition, several controls are essential for distinguishing background from proteasespecific signal, such as negative control without treatment (see Basic Protocol 2, steps 17-27 and 30).
If the animal model used or the protease of interest are different from the ones described in the protocol, we recommend conducting an initial pilot trial on a smaller group of animals. This should help to reduce number of animals and help to optimize the imaging conditions.
Reagent purity and storage
Probes used in assays have to be of the highest purity available to minimize contaminating side products. Purification of cysteine-labeled peptide is generally performed by HPLC. Luciferin and CBTs derivatives should be kept protected from direct light during experiment and storage. In order to maximize possible signal production, buffers have to be degassed when possible to avoid oxidation of cysteine and its derivatives. All the solutions that are to be injected in animals have to be sterilefiltered or sterile buffers have to be used for preparation of solutions.
Acquisition of bioluminescence signal
For all the experiments (cell-free and in vivo), it is recommended to acquire a sequence of data over time for at least one hour by taking measurements every 1 to 10 min. One acquisition per minute is usually a good starting point. It is also important to do the same for measuring the signal from luciferin alone, as this signal changes several fold over time and therefore one-point measurement will certainly lead to significant mistakes in calculations.
Caspase activation
Activation of caspase 3/7 in mice using LPS/D-GalN may result in pain and distress in animals. Therefore, this experiment should be performed in agreement with the legislation that applies in the country where the experiments are realized.
Troubleshooting
Troubleshooting guides for "cell-free" and "live mice" protease activity imaging experiments are presented in Table 1 .
Anticipated Results
Detection of apoptosis has become an important factor in understanding tumor pathology and finding new antitumor treatment. This assay can be used to investigate the apoptotic profile of diseases and also to evaluate cytotoxicity of drugs in vitro and in vivo by measuring accurately cell death parameters.
Figures 5 and 6 demonstrate the examples of data expected from cell-free assays. Figure 8 represents an example of results that can be obtained from in vivo experiments.
The signal to background ratio obtained is the key parameter in these experiments. A significant difference in bioluminescent light emission between treated and untreated animals is expected for both types of assays.
Time Considerations
Once all the necessary reagents are obtained, the described procedure for cell-free test tube assays can be performed within a day. In practice, a few more days should be considered if optimization process is necessary. Experiments in live animals described in the paper typically take three days. However, if taking into account the initial pilot trial in small group of animals in order to optimize conditions, a week or two could be required.
